Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis

Next Previous
Trial Profile

An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Larsucosterol (Primary)
  • Indications Alcoholic hepatitis
  • Focus Adverse reactions
  • Sponsors DURECT Corporation

    • Most Recent Events

    • 01 Jan 2024 Results assessing the safety and pharmacokinetics of larsucosterol in subjects with alcohol-associated hepatitis, published in the American Journal of Gastroenterology.
    • 10 Apr 2023 According to DURECT Corporation media release, additional data from this Phase 2a trial evaluating larsucosterol in alcohol-associated hepatitis has been accepted by the peer-reviewed journal American Journal of Gastroenterology.
    • 29 Aug 2020 Results assessing the safety and pharmacokinetics of DUR-928 in moderate and severe AH patients, presented at The International Liver Congress 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top